1563-56-0Relevant articles and documents
Synthesis of 1,5-substituted iminodibenzo[b,f][1,5]diazocine, an analogue of Troeger's Base
Leganza, Alessandro,Bezze, Chiara,Zonta, Cristiano,Fabris, Fabrizio,De Lucchi, Ottorino,Linden, Anthony
, p. 2987 - 2990 (2006)
A method for the synthesis of 1,5-disubstituted iminodibenzo[b,f][1,5] diazocines is presented. The synthesis is achieved by the metal-free cyclization of 2-aminophenyl ketimines using the corresponding 2-aminophenyl ketone as the catalyst. The synthesis gives new insight into the mechanism of formation of this class of compounds. The presence of potential sites for hydrogen-bond formation and two aromatic bromine atoms available for functionalization make these targets attractive for further development in supramolecular chemistry. The structure of the complex derived from the iminodibenzo[b,f][1,5]diazocine and PdCl2 was determined by X-ray crystallography. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.
Stability indicating spectrophotometric methods for quantitative determination of bromazepam and its degradation product
A. Ali, Nesma,Abdelrahman, Maha M.,Al-Hossaini, Abdullah M.,Darwish, Hany W.,El Ghobashy, Mohamed R.,Naguib, Ibrahim A.
, (2020)
Four simple, sensitive and selective stability indicating spectrophotometric methods are presented for quantitative determination of the benzodiazepine drug; bromazepam (BMZ) and one of its reported potential impurities and degradation product; 2-(2-amino-5-bromobenzoyl) pyridine (ABP) in methanol. Method A, is isoabsorptive point coupled with D0 method, where good linearity was obtained by measuring the absorbance of BMZ at 264 nm (Aiso) in the concentration range of 2–25 μg mL?1, and the absorbance of ABP at its λmax 396 nm in concentration range of 0.5–24 μg mL?1. Method B, is ratio subtraction; the absorbance was measured at 233 nm for BMZ using 20 μg mL?1 of ABP, while ABP was determined directly at its λmax 396 nm using methanol as a solvent. Method C, was based on measuring the total peak amplitude of the first derivative of the ratio spectra (DD1) of BMZ from 301 to 326 nm using 10 μg mL?1 of ABP as a divisor and determination of ABP at peak amplitude of 293 nm using 5 μg mL?1 of BMZ as a divisor. In method D, ratio difference method, good linearity was achieved for determination of BMZ and ABP by measuring the differences between the amplitudes of ratio spectra at 312 nm and 274 nm and differences between the amplitudes of ratio spectra at 274 nm and 312 nm, respectively. The stability of BMZ was investigated under different ICH recommended forced degradation conditions. The suggested methods were then successfully applied for determination of BMZ in its pharmaceutical formulations.
Synthesis method of 2-(2-amino-5-bromobenzoyl) pyridine
-
, (2020/02/19)
The invention discloses a synthesis method of 2-(2-amino-5-bromobenzoyl)pyridine. The method comprises the following processing steps: S1, reacting 4-bromo-2-bromomethylphenol, used as an initial rawmaterial, with MEMCl in an aprotic solvent to obtain 4-bromo-2-(bromomethyl)-1-((2-methoxyethoxy)methoxy)benzene; S2, reacting the 4-bromo-2-(bromomethyl)-1-((2-methoxyethoxy)methoxy)benzene with trimethyl borate under the action of a catalyst to prepare a boric acid compound (5-bromo-2-(((2-methoxyethoxy)methoxy)benzyl) boric acid; and S3, adding 2-bromopyridine and [1,1'-bis(diphenylphosphino)ferrocene]-palladium dichloride into the (5-bromo-2-(((2-methoxyethoxy)methoxy)benzyl)boric acid in order to prepare 2-(5-bromo-2-(((2-methoxyethoxy)methoxy)benzyl)pyridine. The method has the advantages of high atom utilization rate, environmental friendliness due to the recoverable solvent, high yield, convenience in operation, and suitableness for industrial production.
Preparation method of benzodiazepine derivatives
-
Paragraph 0050-0051; 0075; 0076; 0077-0079, (2018/07/30)
The invention relates to a preparation method of benzodiazepine derivatives. The preparation method comprises preparing a compound shown in the formula (III) from a compound shown in the formula (V),preparing a compound shown in the formula (II) through a reaction and finally preparing benzodiazepine derivatives shown in the formula (I) and their pharmaceutically acceptable salts. The invention also discloses an intermediate in the preparation process and a preparation method thereof. The preparation method shortens the reaction processes, improves the reaction yield, is simple, is easy to operate and control and is conducive to expanded production.
DIHYDROQUINAZOLINONE ANALOGUES AS BRD4 INHIBITORS
-
Page/Page column 62, (2014/10/15)
The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
DIHYDROQUINAZOLINONE ANALOGUES
-
Paragraph 0303-0306, (2014/10/16)
The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
-
Page/Page column 60-61, (2008/06/13)
The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.
SHORT-ACTING BENZODIAZEPINES
-
Page/Page column 11, (2008/06/13)
It has now been found that compounds of the present invention as described in Benzodiazepine derivatives of Formula (I) containing a carboxylic ester moiety and thereby capable of being inactivated by nonspecific tissue esterases in an organ-independent elimination mechanism and thereby providing a more predictable and reproducible pharmacodynamic profile. The compounds of the present invention are suitable for therapeutic purposes, including sedative-hypnotic, anxiolytic, muscle relaxant and anticonvulsant purposes and are useful to be administered intravenously in the following clinical settings: preoperative sedation, anxiolysis, and amnestic use for perioperative events; conscious sedation during short diagnostic, operative or endoscopic procedures; as a component for the induction and maintenance of general anesthesia, prior and/or concomitant to the administration of other anesthetic agents; ICU sedation.
Kinetics of the acid hydrolysis of diazepam, bromazepam, and flunitrazepam in aqueous and micellar systems
Moro,Novillo-Fertrell,Velazquez,Rodriguez
, p. 459 - 468 (2007/10/02)
A kinetic study of the acid hydrolysis of aqueous diazepam, bromazepam, and flunitrazepam was carried out at 25 °C using a spectrophotometric method. For diazepam and flunitrazepam, the experimental pseudo first-order rate constant decreased as the acid concentration was increased. The contrary behavior was found in the case of bromazepam. A kinetic scheme that includes the hydrolysis reaction of both protonated and nonprotonated species of the drug can account for these results. Also, the kinetics of the acid hydrolysis of the same drugs in the presence of micellar aggregates [nonionic polyoxyethylene-23-dodecanol (Brij 35); cationic cetyl trymethyl ammonium bromide (CTAB); and anionic sodium decyl (SdeS), dodecyl (SDS), and tetradecyl (STS) sulfate] was studied at 25 °C. Negligible effects were observed in the cases of nonionic and cationic micelles. Anionic micelles produced an inhibitory effect in the reaction velocity. This effect increased as the hydrophobic nature of the surfactant increased. All these facts are interpreted quantitatively by means of a pseudophase model.
